Anti-MIP-1 alpha/CCL3 + CCL4/MIP-1 beta antibody [EPR19900-275] - BSA and Azide free (Capture)

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.

Activity summary

MIP-1 alpha also known as CCL3 and MIP-1 beta known as CCL4 are key chemokines involved in the immune response. These proteins have a molecular mass of approximately 8 to 10 kDa. They are secreted by various cells including macrophages dendritic cells and lymphocytes. MIP-1 alpha and MIP-1 beta are part of the CC chemokine family and are secreted as monomers that bind to specific receptors on the surface of target cells attracting and activating them during inflammation and immune responses.

Biological function summary

These chemokines play significant roles in the recruitment and activation of leukocytes to sites of infection or injury. They are important elements in the immune defense system and help to orchestrate the movement and coordination of immune cells. MIP-1 alpha and MIP-1 beta function in synergy with other chemokines and cytokines enhancing the body's ability to respond to pathogens. While they do not form part of a larger complex their interaction with chemokine receptors like CCR1 CCR4 and CCR5 is critical for their function.

Pathways

MIP-1 alpha and MIP-1 beta participate in inflammatory and immune pathways. They are key mediators in the chemokine signaling pathway linked especially with the activation of the MAPK and NF-kB pathways. These chemokines work closely with related chemokines such as CCL5 (RANTES) and cytokines like TNF-alpha amplifying the body's response to immune challenges.

Associated diseases and disorders

MIP-1 alpha and MIP-1 beta have connections to several pathological conditions particularly inflammatory diseases and HIV. Their levels often increase in diseases like rheumatoid arthritis reflecting their role in inflammatory processes. In the context of HIV infection these chemokines inhibit viral entry by blocking the CCR5 receptor which is important for some strains of the virus. This highlights their therapeutic potential in designing treatments targeting HIV alongside other inflammatory conditions.